WESTMINSTER, Colo., Jan. 25, 2012 /PRNewswire/ -- GeneThera, Inc. (OTCQB: GTHR) announced today that it has acquired a majority ownership of Applied Genetics, a molecular diagnostic company based in Monterrey, Mexico. Applied Genetics is a molecular diagnostic company that focuses on commercializing molecular testing for Johne's disease in Mexico.
This acquisition is part of a broader strategy aimed at quickly initiating Applied Genetics revenue-generating operation.
Dr. Tony Milici, CEO of GeneThera and Interim President of Applied Genetics, commented on the news: "We are very pleased to have reached an agreement with the other shareholders of Applied Genetics to acquire a controlling interest in the company. We will continue our efforts to make GeneThera a leader in molecular diagnostic testing both in Mexico and South America."
Johne's disease is a global devastating and incurable disease of dairy cows, sheep, and goats caused by a bacterium called Mycobacterium Paratuberculosis sub. Avium, (MAP). An overwhelming number of studies have shown that MAP is the causative agent of Crohn's disease in humans. Dairy products, contaminated with MAP, are the vehicles by which the infection spreads in the human intestine. Applied Genetics employs the use of GeneThera HerdCheck™ to test and control the spread of Johne's disease in Mexico. HerdCheck™ is a proprietary molecular diagnostic system based on the use of high throughput robotics and Real time PCR.
About GeneThera, Inc.
GeneThera, Inc. is a molecular biotechnology company located in Westminster, Colorado. The Company's proprietary diagnostic solution is based on a genetic expression assay, GES™ and Johne's disease management system, HERDCHECK™, designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES™ and
|SOURCE GeneThera, Inc.|
Copyright©2010 PR Newswire.
All rights reserved